Pokaż cały numer - FPN - Farmaceutyczny PrzeglÄ d Naukowy

Farm Przegl Nauk, 2010, 73. McMurray JJ, Pfeffer MA. Heart failure. The Lancet,2005; 365: 1877-1886.4. Jackson G, Gibbs CR, Davies MK, Lip GYH. ABC ofheart failure. Patophysiology, 2000; 320: 167-170.5. Matsumori A. Role of inflammation in heart failure. IntJ Cardiol, 2008; 125: 10-11.6. Anker SD, van Haeling S. Inflammatory mediators inchronic heart failure: an overview. Heart, 2004; 90:464-470.7. Marucci R et al. Markers of hypercoagulability and inflammationpredict mortality in patients with heart failure.J Thromb Haemost, 2006; 4: 1017-1022.8. The Task Force on Heart Failure of the European Societyof Cardiology (ESC) developed in collaborationwith the Heart Failure Association of the ESC (HFA).ESC Guidelines Desk Reference. Compendium ofabridged ESC guidelines, 2008; Section XV, Heart Failure:313-338.9. Anand IS et al. C-reactive protein in heart failure: prognosticvalue and the effect of valsartan. Circulation,2005; 112: 1428-1434.10. Guliz K, Gokhan E, Kilic T, et al. Elevated level of highsensitivity C-reactive protein is important in determiningprognosis in chronic heart failure. Med Sci Monit,2010; 16(3): 156‐161.11. Alonso‐Martinez JL, Llorente‐Diez B, Echegaray‐AgaraM, et al. C‐reactive protein as a predictor of improvementand readmission in heart failure. Eur J Hear Fail,2002; 4: 331‐336.12. El-Menyar A. Cytokines and Myocardial Dysfunction:State of the Art. J Card Fail, 2008; 14: 61-74.13. Huang WP, Yin WH, Jen HL, et al. C-reactive proteinlevels in chronic congestive heart failure. Acta CardiolSin, 2004; 20: 7-14.14. Olsson LG, Swedberg K, Cleland J, Spark PA, KomajdaM, Metra M, et al. Prognostic importance of plasma NTproBNP in chronic heart failure in patients treated witha beta-blocker: results from the Carvedilol Or MetoprololEuropean Trial (COMET) trial. Eur J Heart Fail,2007; 9(8): 795-801.15. Richard M, Troughton RW. NT-proBNP in heart failure:therapy decisions and monitoring. Eur J Heart Fail,2004; 6: 351-354.16. Jourdain P, Jondeau G, Funck F, Gueffet P, Le HellocoA, Donal E, et al. Plasma brain natriuretic peptide-guidedtherapy to improve outcome in heart failure. JACC,2007; 49(16): 1733-1739.17. Lamblin N, Mouquet F, Hennache B, Joel D, Susen S,Bauters Ch, et al. High-sensitivity C-reactive protein: potentialadjunct for risk stratification in patients with stablecongestive heart failure. Eur Jeart J, 2005; 26: 2245-2250.18. Alehagen U, Dahlstrom U, Lindahl TL, et al. ElevatedD‐dimer level is an independent risk factor for cardiovasculardeath in out‐patients with symptoms compatible withheart failure. Thromb Haemost, 2004; 92: 1250-1258.19. Kannel WB, D’Agostino RB, Belanger AJ. Update onfibrinogen as a cardiovascular risk factor. Ann Epidemiol,1992; 2(4): 457-66.20. Witte KKA, et al. Fibrinogen synthesis is increased incachectic patients with chronic heart failure. Int J Cardiol,2008; 129(3): 363-367.21. Ferketich AK, Binkley PF. Heart failure and inflammation:results from the third national health and nutritionexamination survey (NHANES III). Cardiac Failure,2004; 10(4): 93.22. Hoffmeister A, et al. Plasma viscosity and fibrinogen inrelation to haemodynamic findings in chronic congestiveheart failure. Eur J Heart Fail, 1999; 1: 293-295.data otrzymania pracy: 15.02.2010 r.data akceptacji do druku: 21.06.2010 r.Corresponding author:Eng. Aleksander Owczarek, Ph.D.Division of Statistics, Department of Instrumental AnalysisMedical University of Silesia30 Ostrogórska S.41-200 SosnowiecMobile: +48 0 501 357 068tel.: +48 32 364 13 32e-mail: aowczarek@sum.edu.pl14